502 related articles for article (PubMed ID: 28595516)
1. Cellular immunotherapy of cancer: an overview and future directions.
Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
[TBL] [Abstract][Full Text] [Related]
2. T lymphocyte therapy of cancer.
Michálek J; Büchler T; Hájek R
Physiol Res; 2004; 53(5):463-9. PubMed ID: 15479123
[TBL] [Abstract][Full Text] [Related]
3. Adoptive cell therapy: past, present and future.
Cohen JE; Merims S; Frank S; Engelstein R; Peretz T; Lotem M
Immunotherapy; 2017 Jan; 9(2):183-196. PubMed ID: 28128715
[TBL] [Abstract][Full Text] [Related]
4. [Cellular immunotherapy of cancer].
Kawakami Y
Rinsho Ketsueki; 2003 Jun; 44(6):358-67. PubMed ID: 12884813
[No Abstract] [Full Text] [Related]
5. Current status and future applications of cellular therapies for cancer.
Copier J; Bodman-Smith M; Dalgleish A
Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
[TBL] [Abstract][Full Text] [Related]
6. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
7. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
8. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
9. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
10. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
11. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
12. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
[TBL] [Abstract][Full Text] [Related]
13. Engineering better immunotherapies via RNA interference.
Sioud M
Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
[TBL] [Abstract][Full Text] [Related]
14. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
15. Recruiting T cells in cancer immunotherapy.
Yost KE; Chang HY; Satpathy AT
Science; 2021 Apr; 372(6538):130-131. PubMed ID: 33833111
[No Abstract] [Full Text] [Related]
16. Marrow-Infiltrating Lymphocytes Are Effective in Multiple Myeloma.
Cancer Discov; 2015 Jul; 5(7):689. PubMed ID: 26022609
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
18. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
Gowrishankar K; Birtwistle L; Micklethwaite K
Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
20. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
